Evidence map›Paper›PMID 34350068›Full record

ArticleIEEE journal of translational engineering in health and medicine2021

Multi-Compartment Spatially-Derived Radiomics From Optical Coherence Tomography Predict Anti-VEGF Treatment Durability in Macular Edema Secondary to Retinal Vascular Disease: Preliminary Findings.

Sudeshna Sil Kar, Duriye Damla Sevgi, Vincent Dong, Sunil K Srivastava, Anant Madabhushi, Justis P Ehlers

Open access · goldAbstract read
In one paragraph

Article in IEEE journal of translational engineering in health and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Artificial Intelligence in Diabetes Care: Applications, Challenges, and Opportunities Ahead.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sudeshna Sil KarDepartment of Biomedical EngineeringCase Western Reserve UniversityClevelandOH44106USA.
Duriye Damla SevgiThe Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advancing Imaging ResearchCleveland Clinic Cole Eye InstituteClevelandOH44106USA.
Vincent DongDepartment of Biomedical EngineeringCase Western Reserve UniversityClevelandOH44106USA.
Sunil K SrivastavaThe Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advancing Imaging ResearchCleveland Clinic Cole Eye InstituteClevelandOH44106USA.
Anant MadabhushiDepartment of Biomedical EngineeringCase Western Reserve UniversityClevelandOH44106USA.
Justis P EhlersThe Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advancing Imaging ResearchCleveland Clinic Cole Eye InstituteClevelandOH44106USA.
Case Western Reserve University · USCleveland Clinic · US

Funding

Pathology CoreU54CA254566 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2020 to 2024
$5.0M
Computer-Assisted Histologic Evaluation of Cardiac Allograft RejectionR01HL151277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MADABHUSHI, ANANT, MARGULIES, KENNETH BER · 2020 to 2023
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
Pathology Image Informatics Platform for visualization, analysis and managementU24CA199374 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GURCAN, METIN NAFI, MADABHUSHI, ANANT · 2015 to 2019
$2.9M
Novel Radiomics for Predicting Response to Immunotherapy for Lung CancerR01CA257612 · NCI · EMORY UNIVERSITY · PI Anant Madabhushi, Vamsidhar Velcheti · 2021 to 2026
$2.7M
RadxTools for assessing tumor treatment response on imagingU01CA248226 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI TIWARI, PALLAVI, VISWANATH, SATISH EASWAR · 2020 to 2022
$1.4M
HistoTools: A suite of digital pathology tools for quality control, annotation and dataset identificationU01CA239055 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JANOWCZYK, ANDREW ROBERT, MADABHUSHI, ANANT · 2019 to 2022
$1.0M
Intraoperative Optical Coherence Tomography for Ophthalmic SurgeryK23EY022947 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI EHLERS, JUSTIS · 2013 to 2017
$1.0M
A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear SlidesR43EB028736 · NIBIB · DIASCOPIC, LLC · PI MADABHUSHI, ANANT, SERIF, CARY · 2019 to 2019
$225k
BLRD VA I01 BX004121NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220581NCI NIH HHS R01 CA257612NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U24 CA199374NCI NIH HHS U54 CA254566NCRR NIH HHS C06 RR012463NEI NIH HHS K23 EY022947NHLBI NIH HHS R01 HL151277NIBIB NIH HHS R43 EB028736
6 · The paper itself

Abstract

objectiveDiabetic macular edema (DME) and retinal vein occlusion (RVO) are the leading causes of visual impairments across the world. Vascular endothelial growth factor (VEGF) stimulates breakdown of blood-retinal barrier that causes accumulation of fluid within macula. Anti-VEGF therapy is the first-line treatment for both the diseases; however, the degree of response varies for individual patients. The main objective of this work was to identify the (i) texture-based radiomics features within individual fluid and retinal tissue compartments of baseline spectral-domain optical coherence tomography (SD-OCT) images and (ii) the specific spatial compartments that contribute most pertinent features for predicting therapeutic response.

methodsA total of 962 texture-based radiomics features were extracted from each of the fluid and retinal tissue compartments of OCT images, obtained from the PERMEATE study. Top-performing features selected from the consensus of different feature selection methods were evaluated in conjunction with four different machine learning classifiers: Linear Discriminant Analysis (LDA), Quadratic Discriminant Analysis (QDA), Random Forest (RF), and Support Vector Machine (SVM) in a cross-validated approach to distinguish eyes tolerating extended interval dosing (non-rebounders) and those requiring more frequent dosing (rebounders).

resultsCombination of fluid and retinal tissue features yielded a cross-validated area under receiver operating characteristic curve (AUC) of 0.78±0.08 in distinguishing rebounders from non-rebounders.

conclusionsThis study revealed that the texture-based radiomics features pertaining to IRF subcompartment were most discriminating between rebounders and non-rebounders to anti-VEGF therapy. Clinical Impact: With further validation, OCT-based imaging biomarkers could be used for treatment management of DME patients.

Indexed as

Diabetic RetinopathyMacular EdemaAngiogenesis InhibitorsHumansIntravitreal InjectionsTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsVascular Endothelial Growth Factor ADiabetic macular edema (DME)Intravitreal Aflibercept Injection (IAI)optical coherence tomography (OCT)radiomicsvascular endothelial growth factor (VEGF)

Identifiers

PMID34350068
PMCPMC8328398
OpenAlexW3182835359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.